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C O M M I T T E E   R E P O R T
In 1990, a subcommittee of the Scientific Section Coor-dinating Committee (SSCC) of the AABB formulatedguidelines for prenatal and perinatal immunohemato-logic  testing.1 These guidelines were published to pro-
vide transfusion service directors and supervisors with an
authoritative source for reference in discouraging the use of
outmoded tests and practices.
Several changes have occurred in the decade since the
SSCC guidelines were published. First, with the development
of managed-care programs, routine testing is ordered by the
primary care giver and often is performed by commercial
laboratories. The extent to which hospital transfusion ser-
vices need to repeat such tests for medicolegal reasons can
be questioned, and there is an understandable reluctance on
the part of health insurance companies to reimburse for such
confirmatory testing. Second, the administration of Rh im-
mune globulin (RhIg) prophylaxis is now often the responsi-
bility of outpatient clinic nurse managers, rather than being
under the purview of the transfusion service. Third, changes
in regulations disallow reimbursement for laboratory tests
not ordered by a licensed physician. Fourth, there have been
changes in reagents and test methods, and considerable
knowledge has been gained about the molecular basis and
structure of blood group polymorphisms, especially those
of the Rh blood group system.
In light of these changes, it has become necessary to relax
some of the previous guidelines and, in other cases, to intro-
duce new ones. The following represents current opinions
on prenatal and perinatal testing.
PURPOSE OF PRENATAL AND
PERINATAL TESTING
The objectives of prenatal and perinatal testing are essen-
tially threefold: 1) to identify D– women; 2) to identify women
with potentially significant alloantibodies to RBC antigens;
and 3) to assist in the diagnosis and management of HDN,
both during pregnancy and at delivery. Once a woman is iden-
tified as D–, RhIg therapy can be administered during preg-
nancy to prevent alloimmunization to D, and tests can be
performed to determine the need for RhIg at delivery and
the dose required. In pregnancies in which the mother is
alloimmunized, the role of the transfusion service is to de-
termine antibody specificity and, when potentially significant
antibodies are present, to monitor antibody levels. The data
obtained are used to determine if and when to monitor for
HDN by other means, such as amniocentesis.2 When HDN is
present, it is the role of the blood bank to provide the appro-
priate blood components for transfusion to the affected fe-
tus or newborn infant. When HDN is suspected but the ma-
ternal serum appears to lack unexpected antibodies or is
unavailable, the services of the immunohematology labora-
tory are required to exclude or identify an immunologic basis
for the infant’s clinical condition. Most often this entails test-
ing for ABO incompatibility between mother and child, al-
though on occasion the maternal serum will be found to
contain antibody to a paternally derived antigen that is of
low prevalence in the general population.
ROUTINE TESTING DURING PREGNANCY
ABO and D testing
All women should be tested for ABO and D as early as pos-
sible during each pregnancy, preferably at their first-trimes-
ter visit.1 ABO typing is done primarily to aid in patient iden-
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tification, especially if transfusions become necessary. A re-
cord of the maternal ABO type can also be helpful should
the newborn infant develop clinical signs and symptoms
consistent with ABO HDN. The results should not conflict
with historical records, and discrepant reactions must be fully
investigated and resolved.3 Table 1 gives a summary of cur-
rent recommendations for prenatal testing.
Past editions of the standards of the AABB mandated
that the D typing be repeated each time a woman was ad-
mitted for termination of pregnancy, an invasive procedure
such as amniocentesis, or delivery. The 1990 guidelines1 rec-
ommended that no further D testing is necessary once con-
cordant results are obtained on blood samples collected on
two separate occasions. This recommendation applies to all
first pregnancies, even if the initial blood sample is typed as
D+. [NB: A grave injustice is done to a D– pregnant woman
who is falsely typed as D+ as a result of patient-sample mis-
identification or laboratory error, because she will not re-
ceive RhIg therapy.] Thereafter, the patient’s D type should
be verified at each obstetric visit by review of the medical
records. Serologic confirmation of the D type is recommended
at the beginning of each subsequent pregnancy.3
Process controls should be in place to prevent false typ-
ing of a D– woman as D+. Such measures might include re-
identification of the sample and then a test with a second
anti-D reagent (to prevent laboratory errors due to sample
misidentification), as well as methods to detect false-posi-
tive tests due to spontaneous agglutination of RBCs.4(p307-312)
Testing for weak expression of D (if performed) should be
done according to the test manufacturer’s instructions, us-
ing anti-IgG rather than anti-IgG+C3 antiglobulin reagents
to prevent false-positive tests due to complement coating of
the RBCs. The test for weak D should not be read micro-
scopically. Further, if Rh typing is performed during the third
trimester or at delivery, there must be established mecha-
nisms and interpretation criteria to prevent mistyping of a
D– woman as D+ due to a large fetomaternal hemorrhage
(FMH).5 Only when prenatal tests for Rh are clearly reactive
(>2+) should the woman be considered D+.1
Testing for weak D
Testing for weak expression of D is optional. One consequence
of not typing for weak D early in pregnancy is that phenotypi-
cally weak D women will receive RhIg therapy that, arguably,
they may not need. RhIg has not been entirely “risk free” with
respect to transmission of infectious disease, notably HCV, and
this should be kept in mind in the formulation of testing pro-
tocols. On the other hand, with current FDA-licensed reagents,
women of a partial D phenotype, such as category VI, or DVI,
will likely type as D– in direct tests with anti-D and, in the ab-
sence of a test for weak D, will, again arguably, be candidates
for antepartum RhIg therapy. Some confusion may occur af-
ter delivery, when the RBCs of an unrecognized weak D woman
are subjected to the rosette test for FMH6; a diffuse rosetting
of D+ indicator RBCs will be observed. In such a situation, a
test for weak D can be performed on a predelivery (admis-
sion) specimen. This avoids false-positive tests for weak D due
to massive FMH.7
Whether RhIg will be beneficial in preventing D alloim-
munization in women of a partial D phenotype is a matter for
conjecture. It could be argued that most of the RhIg would
bind to the D epitopes that are present on the maternal RBCs;
consequently, there would not be sufficient RhIg available to
prevent alloimmunization by D+ fetal RBCs. More than the
normal dose of RhIg may be required.8 However, the exact
mechanism by which RhIg prevents alloimmunization to D is
not known, so the need for the anti-D to be free in the plasma
to prevent alloimmunization is also a matter for conjecture.
Wagner et al.9 argue that the D type of pregnant women
(as well as potential transfusion recipients) should be deter-
mined by using two D MoAb reagents, one of which does not
detect the weak D of DVI RBCs. In their opinion, women of the
DVI phenotype are candidates for RhIg therapy. This opinion
is based on their molecular analysis of weak D phenotypes.
Clearly, the decision to perform a test for weak D on
apparently D– pregnant women is at the discretion of the
TABLE 1. Recommended prenatal testing
Testing and condition Timing
ABO
First pregnancy Initial visit
Subsequent pregnancies Initial visit
Other For pretransfusion testing
Rh (test for weak D optional)
First pregnancy Initial visit and at
  26-28 weeks’ gestation
Subsequent pregnancies Initial visit
Other For pretransfusion testing
Unexpected antibodies
All pregnancies Initial visit
D– pregnancies Before RhIg therapy
  (optional)
D+ pregnancies Third trimester if
  transfused or history of
  unexpected antibodies
Other For pretransfusion testing
Antibody identification
Unexpected antibodies Upon initial detection
  present
Confirmatory testing At time of titration
Antibody titration
Rh antibodies Upon initial detection
Repeat at 18-20 weeks’
  gestation
Repeat at 2 to 4-week
  intervals if below
  critical titer (16-32)
Other potentially As above, with discussion
  significant antibodies   with obstetrician
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transfusion service medical director. If the decision is made
to include a test for weak D and the test is clearly positive,
the woman should be regarded as D+ and treated as such.
This appears to be the most common practice in the United
States. If testing for weak D is not performed, women whose
RBCs do not react in direct tests with anti-D can be consid-
ered candidates for RhIg therapy, both during pregnancy and
at delivery.
Testing for unexpected antibodies
Initial testing. All women, regardless of their D type, should
be tested during each pregnancy for clinically significant
unexpected serum antibodies, ideally at their first visit to the
obstetrician. Antiglobulin testing should be done with anti-
IgG to detect preferentially those antibodies with the poten-
tial to cross the placenta and cause HDN. The methods (e.g.,
LISS, PEG, gel, solid-phase adherence) used to detect unex-
pected antibodies during pretransfusion testing4 can be used
for prenatal antibody detection. The use of enzyme-treated
RBCs or polyspecific anti-human globulin is not advocated,
as both promote unwanted positive reactions.1
Testing before antepartum RhIg prophylaxis. An addi-
tional screening test for unexpected antibodies may be re-
quested for D– women at 26 to 28 weeks’ gestation, to deter-
mine if active immunity to D exists, before the administration
of RhIg prophylaxis. The risk of the occurrence of D alloim-
munization between the first-trimester visit and 28 weeks’
gestation is quite low, on the order of 0.18 percent.10 Further,
there is a paucity of cases in which anti-D not detected at the
first-trimester visit has developed during pregnancy and
caused significant HDN requiring medical intervention be-
fore delivery. However, the cost-effectiveness of repeat test-
ing has not been studied. Clearly, elimination of the test for
unexpected antibodies before RhIg administration is some-
thing that should be considered. In the past, this testing was
dictated by RhIg product circulars (product not indicated if
alloimmunization to D exists), but such wording is no longer
included in the product circulars. The recent practice guide-
lines11 issued by the American College of Obstetricians and
Gynecologists state that the decision to repeat the antibody
screen is dictated by individual circumstances and the judg-
ment of the obstetrician. When a repeat test is requested, the
sample should be obtained before the administration of RhIg,
but RhIg need not be withheld pending the results.1
Third-trimester testing. In most cases, D+ patients need
be screened for antibodies only once during pregnancy, at
the initial visit. In a study12 of 9,348 D+ obstetric patients who
had first-trimester and third-trimester tests for unexpected
antibodies, only 6 patients (0.06%) developed new antibod-
ies capable of causing HDN. In another study of 17,568 preg-
nancies, Heddle and colleagues13 found 58 cases (0.24%) in
which potentially significant alloantibodies were detected for
the first time at delivery. In both studies, no significant neo-
natal sequelae resulted from these newly formed antibod-
ies. Therefore, routine testing for unexpected antibodies in
the third trimester or at delivery will rarely yield useful in-
formation.
Regardless of D type, additional testing is appropriate
when there is a history of significant antibodies, blood transfu-
sions, or traumatic deliveries.1 Antibody detection tests will
also be required when pretransfusion tests are requested, and
a maternal sample may be needed for neonatal pretransfusion
evaluation or investigation of HDN.
Testing after RhIg administration. Requests to per-
form titration studies, to differentiate passive immunity to
D from active, after antenatal or postpartum RhIg therapy
should be vigorously discouraged. A low titer (e.g., 2) does
not preclude active immunity, and, if the titer is high, the
infant will likely manifest clinical signs and symptoms of
HDN. Evidence for active immunity to D can best be ob-
tained by performing antibody detection tests 6 months
after delivery or at the initial visit for the next pregnancy.
Anti-D found for the first time at delivery should be assumed
to be due to antepartum RhIg therapy until proven other-
wise. The mother is a candidate for postpartum RhIg and
assessment of FMH.1 To exclude the presence of
non-D antibodies after RhIg administration, Shulman and
colleagues14 advocate the use of selected D– RBCs; a set of
three such RBC samples (r´r, r´´r, and rr) is currently avail-
able from reagent manufacturers in the United States.
ALLOIMMUNIZATION AND PREGNANCY
Antibody identification
If tests for unexpected antibodies are positive at any time
during pregnancy, the blood group specificity of the anti-
body should be identified.1 The same methods used for
antibody detection can be used for identification.4 It should
not be assumed that an antibody present in a D– woman is
anti-D, even after RhIg therapy. As discussed above, a lim-
ited-reagent RBC panel can be used to exclude clinically
significant antibodies other than D.
Results of antibody identification tests help determine
if the antibody is likely to cause HDN. IgG antibodies di-
rected toward antigens such as those of the Chido/Rodgers
and Knops systems do not cause accelerated destruction
of incompatible RBCs and, therefore, are unlikely to be im-
plicated in HDN. In contrast, Rh and other IgG antibodies
known to cause accelerated destruction of incompatible
RBCs are usually considered capable of causing HDN. The
notable exceptions to this appear to be antibodies to Cromer
system antigens.15
There are no reported cases of HDN due to anti-P1, anti-
Lea, or anti-Leb. These antibodies are predominantly IgM and,
as such, do not cross the placenta. In addition, the corre-
sponding antigens are poorly expressed at birth. Thus, no
further testing is warranted when only these specificities are
encountered during pregnancy. Anti-M can be either IgM or
JUDD
1448   TRANSFUSION   Volume 41, November 2001 www.transfusion.org
IgG16 and is often seen in pregnancy, especially when LISS
methods are used for antibody detection. However, anti-M
only rarely causes HDN.17
Titration
Purpose. The purpose of titrating potentially significant an-
tibodies detected in pregnancy is not to predict the severity
of HDN. Coupled with obstetric history, antibody titers are
only 62-percent accurate in predicting severe HDN.18 Rather,
titration is a screening test. It is done to determine when to
monitor for HDN by nonserologic means, such as spectro-
photometric analysis of amniotic fluid. The peak imparted
by bilirubin at 450 nm on the spectral adsorption curve is
plotted against gestational age and is used to predict fetal
anemia.2 If severe anemia appears likely, other means of fe-
tal monitoring may be initiated, such as cordocentesis,19 ul-
trasonography,20 and Doppler assessment of cerebral artery
peak velocity.21 Amniocentesis is usually initiated if there is a
twofold or greater increase in titer during pregnancy or if
the titer equals or exceeds a critical level. In the first preg-
nancy affected with anti-D, either a rising titer or a critical
titer of 16 (determined according to the method described
below) indicate the need to monitor for HDN by amniotic
fluid analysis.22,23 The critical titer will vary from one institu-
tion to another; in most centers, a value of 8 to 32 is used.
Amniocentesis is an invasive procedure and may intro-
duce fetal cells into the maternal circulation. What initially
was an insignificant, low-titer anti-D may become a high-
titer antibody causing severe HDN. Consequently, unless the
obstetric history dictates otherwise, most obstetricians do
not perform amniocentesis until the antibody level reaches
the critical titer. Once the decision has been made to moni-
tor for HDN by an invasive procedure, such as amniocente-
sis, no further titrations are warranted. For Rh antibodies
other than D, there are no data on which to base a critical
titer; however, it is recommended that such cases be man-
aged as though the antibody was anti-D.1
Method. Titration studies should be performed by a
saline antiglobulin procedure that utilizes 60 minutes’ incu-
bation at 37ºC and anti-IgG.1 The use of enzyme-treated
RBCs, LISS, or other enhancement media for titration pur-
poses is contraindicated. Their use undoubtedly accounts for
the wide disparity of values reported in a survey conducted
by the College of American Pathologists.24 Gel column tech-
nology25 should not be used for prenatal antibody titration
until there are substantial data showing correlation between
gel column and saline tube antiglobulin titers. A detailed sa-
line–antiglobulin method is given in the Technical Manual
of the AABB.4(p708-9)
The selection of RBCs for use in prenatal antibody titra-
tion is controversial. Some would say that RBCs with a single-
dose (heterozygous) expression of the offending antigen
should be used, because these reflect the antigen expression
on the fetal RBCs. Others would argue that it is best to err on
the side of safety and use RBCs with a double-dose (homozy-
gous) antigen expression. There is no single policy that is
practical for all antibodies. For anti-D, R2R2 RBCs are the
preferred indicator RBCs, as they tend to carry a uniform
expression of D from one donor to another. R2R2 RBCs are
also the only indicator RBCs required for prenatal titration
purposes in cases involving anti-c, anti-E, anti-cE, and mix-
tures thereof. Except for anti-C+D (see anti-G discussion),
there is no value in determining the titer for each Rh anti-
body in a mixture, because it is the combined effect of the
antibodies that will likely determine the degree of HDN. For
other antibodies, RBCs with a double-dose expression of the
appropriate antigen should be used if readily available. How-
ever, RBCs from homozygotes will probably not be available
for titrating antibodies to antigens of low prevalence. If anti-
bodies that are incapable of causing HDN (e.g., anti-Lea) are
also present, the selected RBCs should lack the correspond-
ing antigens.
Timing of the titration. Titration of potentially signifi-
cant antibodies early in pregnancy is appropriate for assess-
ment of the potential for severe HDN and establishment of
a baseline for comparison to titers found later in pregnancy.
Repeat titration of Rh antibodies, at 2- to 4-week intervals
after 18 weeks’ gestation, is appropriate, providing the data
are used to indicate the need for fetal monitoring by other
means, such as amniocentesis. If a previous sample from the
current pregnancy is available, it should be tested in parallel
with the current sample.1,4
Previously affected fetus or infant. Maternal anti-D ti-
ters are not helpful in following the degree of fetal anemia after
the first affected gestation.26 In the case of a single-dose pa-
ternal phenotype, the D status of the fetus should be ascer-
tained (see below). If the fetus is D+, monitoring for HDN can
be done by serial amniocentesis or middle cerebral artery
Doppler21 at 18 weeks’ gestation (repeat at 2-week intervals).
Titration of non-Rh antibodies. Titration of non-Rh
antibodies should be undertaken only after discussion with
the obstetrician as to the significance of the results and how
the data obtained will affect patient management.1 There are
few data concerning critical titers for non-Rh antibodies
encountered in pregnancy. Goodrick and colleagues27 evalu-
ated 68 pregnancies in which anti-Fya was detected, and they
correlated titers with clinical outcomes. They suggested a
critical titer of 64, at which evaluation for HDN should be
done nonserologically.
Inappropriate titrations. In addition to attempts to dif-
ferentiate between active and passive immunity by titration,
there are situations in which titration studies are inappro-
priate. Clearly, there is no point in titrating non-IgG anti-
bodies, as these will not cause HDN. Except to safeguard
against the possibility of false-negative fetal Rh genotyping
results (see below), there is no point in performing titration
studies once the critical titer has been attained or the deci-
sion made to monitor the pregnancy by an invasive proce-
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dure such as amniocentesis. Antibodies detected at deliv-
ery should not be titrated, as titration studies at this time
serve no useful purpose.1
Recommendations for specific situations
Anti-K. Antibody titers and results of amniotic fluid analysis
in pregnancies affected with anti-K do not correlate with the
severity of fetal anemia. Vaughan and colleagues28 found that
IgG anti-K inhibits the growth of K+ erythroid progenitor cells
in vitro. This finding suggests that suppression of erythropoie-
sis at the progenitor-cell level exacerbates the fetal anemia.
Management of pregnancies involving K alloimmunization
should focus on K genotyping of fetal DNA when the father is
heterozygous for K and on monitoring the K+ fetus for the
development of anemia by cordocentesis and serial ultra-
sonography.
Anti-C+G. Cases of pregnant women with anti-C and
-G but not anti-D are not infrequent. Such cases may appear
to be RhIg failures when RhIg has been administered appro-
priately in previous pregnancies. However, RhIg therapy has
not failed in these patients, and they should receive RhIg dur-
ing pregnancy to prevent immunization to D.29 When anti-G
(but not anti-D) is present, the titer against C+D– RBCs is in-
variably higher than that against C–D+ RBCs (Case J, oral com-
munication, November 2000). It is possible to show that
anti-D is absent by adsorption with r´r (D–C+) RBCs or in di-
rect tests with very rare D+G– RBCs. However, few transfu-
sion service laboratories have such resources. In the absence
of the necessary resources to prove that anti-D is not present,
RhIg therapy is recommended when the titer against r´r
(D–C+) RBCs is higher than that against R2R2 (D+C–) RBCs.
Anti-M. Anti-M is a very rare cause of HDN.17 Most ex-
amples react in direct agglutination tests, which suggests that
they are IgM. However, many examples do have an IgG com-
ponent16 and are often detected through the use of acidic LISS
reagents. Accordingly, the following approach is suggested to
assess the potential for HDN:
1. A saline IAT should be performed with undiluted
serum; if this is nonreactive, the titer can be reported as <1.
2. If the anti-M is reactive in saline IATs, titration studies can
be done according to the method described in  reference 3.
3. If the antiglobulin titer is >16, the presence and titer of IgG
anti-M can be determined after 2-mercap-toethanol treat-
ment of the serum.30 Monitoring for HDN by amniotic
fluid analysis should be considered when the IgG anti-M
titer is >16.
Role of functional assays
The use of a “critical titer” has been denounced by some
European investigators.31 Their criticism is misguided; they
incorrectly assumed that titrations are performed to predict
the severity of HDN. As stated previously, titrations are done
to determine when to monitor the pregnancy for hemolytic
disease by invasive means such as amniocentesis. Simply put,
titrations are done to regulate the use of amniocentesis.
The European workers suggested that functional assays
that measure phagocytosis or cytotoxic lysis should be per-
formed instead. Such assays include the monocyte monolayer
assay (MMA), the chemiluminescence test (CLT), and the an-
tibody-dependent cell-mediated cytotoxicity assay.32 The CLT
appears to be a better predictor of Rh HDN than the MMA.33
However, neither was helpful in predicting HDN due to non-
Rh antibodies.34  Further, CLT results only modestly limit
the number of invasive procedures required.35,36 In contrast,
Oepkes et al.37 found the antibody-dependent cell-mediated
cytotoxicity assay a better indicator than antibody titer for the
need to monitor for HDN by invasive procedures.
Functional assays have not been widely adopted in North
America. In large part, this is due to the fact that prenatal
testing in the United States is not centralized, as it is in Eu-
rope. The functional assays are more complex and thus more
technically difficult to perform than simple titrations, and—
as is required in the current regulatory environment—they
are not easy to validate.
Blood group status of the fetus
It is important to remember that not all potentially signifi-
cant antibodies seen in pregnancy will cause HDN, especially
when the antibody stimulus is unrelated to the current preg-
nancy. For example, the antibodies may be induced by trans-
fusion or may have resulted from a previous pregnancy by a
different consort, in which case the current fetus may be
antigen-negative and not at risk for HDN. Also, it is worth-
while to phenotype RBCs from the putative father whenever
the potential for HDN exists. On the basis of the probable
genotypes that may be deduced, it is possible to predict the
likelihood that the fetus carries the antigen to which the
maternal serum contains antibody.
When there is a high likelihood that the father is het-
erozygous for the gene encoding the offending antigen, mo-
lecular genotyping can be informative. PCR-based amplifi-
cation assays have been developed to determine fetal Rh, K,
Fy, and Jk genotypes by using material derived from amni-
otic fluid or chorionic villi. Avent and colleagues38 recently
reviewed this subject. Noninvasive methods have been de-
veloped to obtain fetal DNA from maternal peripheral blood.
These methods are not without pitfalls. Molecular testing of
both paternal and maternal samples should be done with the
same primers as are used to test the fetal sample. False-posi-
tive results are seen with serologically D– persons who have
an intact but nonfunctional RHD gene. Such persons are in-
frequent among whites, but their frequency is higher among
Japanese and people of African descent. False-negative re-
sults can also occur; analysis of sequences in two or more
exons is essential, and the paternal Rh status should be de-
termined by both molecular and serologic methods. These
two measures can be helpful in preventing or recognizing
JUDD
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false-negative results from the fetal sample. If a paternal
sample is not available, some workers recommend repeat-
ing the maternal antibody titer 4 to 6 weeks later; if there is a
fourfold increase in titer, then a D– fetal result is suspect.39
MANAGEMENT AT DELIVERY
Mother
The following pertains to the management of the mother and
tests on maternal blood at delivery:
1. ABO and D testing should be performed if there are no
records of two concordant results.
2. ABO, D, and antibody detection tests should be used when
pretransfusion tests are requested. Any antibodies detected
for the first time at delivery should be identified. If a woman
has received RhIg during pregnancy, tests should be per-
formed with a limited panel of D– RBCs to detect antibod-
ies other than anti-D, and the practice of performing
titration studies to differentiate between passive and active
immunity to D is unnecessary.
3. In known cases of alloimmunization, confirmation of pre-
viously identified antibodies (including tests for additional
potentially significant antibodies) should be performed.
Requests for titration of antibodies present at delivery
should be actively discouraged; the results serve no useful
clinical purpose.
4. Tests should be performed to assist in the investigation of
HDN (Table 2).
5. All D– women who deliver a D+ fetus should receive at
least a single 300-µg dose of RhIg within 72 hours of deliv-
ery. In addition, a maternal sample should be obtained ap-
proximately 1 hour after delivery and tested for evidence
of an FMH in excess of 30 mL of fetal blood. Testing for
excessive FMH should not be done selectively, as charac-
teristics of the delivery do not predict the likelihood of a
large FMH. Testing for excessive FMH should be done
regardless of the presence of detectable passive anti-D in
the maternal serum. Some obstetricians assume that, if
passive anti-D is detected after the administration of a
single 300-µg dose of RhIg, there is no need for additional
RhIg, but there is absolutely no scientific evidence to sup-
port this assumption.40
A number of methods exist for the detection of massive
FMH. The rosette test is a useful screening method.6 Tests of
artificial mixtures showed that this method yields a positive
test when there is an FMH of 2.5 mL of whole blood; this is
well below the 30-mL FMH volume that should be treated
with additional doses of RhIg. Test kits based on modifica-
tions of the original method are available commercially. If
this test is positive, the degree of FMH can be quantified by
using the Kleihauer-Betke acid-elution method.41 Alterna-
tively, flow cytofluorometric42 or enzyme-linked antiglobu-
lin methods43 can be used for both screening and quantifi-
cation purposes. After the volume of FMH has been
determined, the number of required additional doses should
be administered as soon as possible, preferably within 72
hours of delivery.1
Infant
The following pertains to the testing of cord, capillary (e.g.,
heelprick), or venous blood samples from newborn infants:
1. In the absence of clinically significant unexpected antibod-
ies in the maternal serum, no testing of cord blood samples
is required, except to aid in diagnosis, assist in neonatal
care, or determine the RhIg candidacy of D– mothers. This
position is consistent with practice guidelines for the man-
agement of neonatal jaundice promulgated by the Ameri-
can Academy of Pediatrics.44
TABLE 2. Recommended testing at delivery
Indication
Maternal blood
  ABO/D To obtain concordant results of tests on two samples, or if
  pretransfusion tests requested
  Antibody detection When pretransfusion tests requested
  Antibody identification First detection of alloantibody, D– panel should be used if RhIg
  given during pregnancy
  Titration studies Not indicated
  FMH testing All D– women who deliver an D+ infant
  Testing to diagnose HDN ABO/D and tests for unexpected antibodies if not done during the
   admission for delivery
Test maternal serum against paternal RBCs if there are no unex
   pected antibodies found by routine reagent screen RBCs and
   no fetomaternal ABO incompatibility
Cord or infant blood
  Infants born to D– women D status, including test for weak D
  Infants born to women with potentially significant antibodies ABO, D, and DAT
  No maternal alloimmunization; infant with clinical signs
    and symptoms of HDN ABO/D and DAT
If fetomaternal ABO incompatibility exists, infant serum should
   be tested for IgG anti-A and/or -B
If no fetomaternal ABO incompatibility exists, maternal serum
   (see above) or infant eluate should be tested against
   paternal RBCs
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     Despite this statement, some institutions continue to
perform ABO/D typing and a DAT on all newborns; such
routine testing is not clinically indicated and should be dis-
couraged. Other institutions are more discriminating, and
they routinely do an ABO/D typing and a DAT on infants
born to group O women; here, the intent seems to be to
identify those infants at risk of ABO HDN, and selectively
monitor them for evidence of jaundice. This practice has
evolved with the advent of managed-care programs and
efforts to reduce the length of hospital stay, but it lacks
solid justification: all newborn infants should be monitored
for jaundice during the first week of life.45
2. Blood from infants born to D– women should be tested for
D, including weak D. If the infant is of a weak D phenotype,
the mother is a candidate for RhIg and should be evaluated
for excessive FMH. In this setting, it is inappropriate to use
the rosette test or any other anti-D-based method to assess
for excessive FMH (number of D sites on fetal RBCs will be
low, resulting in false-negative tests). Rather, methods should
be used that detect HbF in fetal RBCs.
3. ABO/D typing and a DAT on the infant's blood are recom-
mended if the mother was not tested for ABO/Rh and
unexpected antibodies during pregnancy. Routine eluate
preparation and testing are not indicated when confirma-
tory antibody identification studies have been performed
on the maternal serum during the admission for delivery.
4. In the absence of a maternal sample, the infant’s blood can
be used for compatibility testing.
5. In the absence of maternal alloimmunization during preg-
nancy, serologic testing of infant blood should be dictated
by development of neonatal jaundice and/or unexplained
anemia. Testing should initially focus on showing ABO in-
compatibility between fetus and mother. An ABO/D typ-
ing and a DAT should be done, although the DAT is often
negative in ABO HDN. When there is fetomaternal ABO
incompatibility, the infant’s serum should be tested for un-
expected antibodies by IAT against reagent group O RBCs
and with at least two examples of group A1 and/or group
B RBCs. The presence of maternally derived IgG anti-A or
anti-B in the infant’s serum is sufficient evidence to sup-
port a diagnosis of ABO HDN. Eluate preparation and test-
ing are not required.
6. In the absence of fetomaternal ABO incompatibility, but
with clinical evidence of HDN, an antibody in the mater-
nal serum to a low-prevalence (paternal) antigen should
be considered. The infant’s DAT will usually be strongly
positive. An IAT should be performed with maternal se-
rum and paternal RBCs. When ABO incompatibility exists
between these samples, an eluate from the infant’s RBCs
can be tested against the paternal RBCs.
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